Executive Director, Medical Affairs, Genitourinary

Job Description

The Executive Director, Value & Implementation Global Medical & Scientific Affairs (V&I GMSA), Global Therapeutic Area (TA), position resides in the V&I organization, which includes GMSA as well as Outcomes Research. This position, referred to as TA EDMA, is accountable for the alignment and execution of the GMSA portion of the Global V&I Plans for their assigned TAs that are disease specific and can involve asset components.

The TA EDMA will allocate 50% of their strategic focus to support the United States (U.S.) and 50% supporting the rest of the world. The TA EDMA may also be appointed as a V&I Lead for their disease/asset area(s), with additional organizationally aligned responsibilities. The TA EDMA fosters relationships and engages with global scientific leaders and key decision-makers to inform the V&I priorities.

The TA EDMA brings subject-matter expertise along with a global view to strategically partner with internal stakeholders around Global V&I priorities.

This position is also a team leader who effectively manages and inspires a diverse team to achieve high performance and deliver exceptional results. The TA EDMA exemplifies our company’s leadership skills—namely, acting as a change catalyst, taking ownership and accountability, and displaying emotional intelligence—and sets these standards for their team.

Primary Responsibilities

• Accountable for the generation of the global strategic V&I plan, its global and regional execution, and facilitating the rollout to the countries. The V&I strategy guides the bidirectional, tactical execution of the V&I GMSA portion in partnership with Outcomes Research to guide real-world data generation.
• Aligns with Big Country Markets. Ensures robust two-way communication with U.S., China, and Japan Executive Directors (Eds) or equivalents. Captures market-specific needs and insights to inform global strategy, while also guiding local execution in alignment with global V&I plans. Integrates into the EDMA Tandem model to foster strategic clarity and executional excellence.
• Demonstrates enterprise leadership across geographies. Dedicates 50% of their strategic focus to the U.S., acting as a change catalyst—leading global planning while ensuring seamless integration with U.S. execution. Partners with U.S. EDMA and Health Systems EDs to align payor strategies, precision-medicine initiatives, and congress deliverables.
• Partners with the appropriate Product Development Team (PDT) and/or Asset Development Team (ADT), Global Brand, and V&I Outcomes Research leads to define clinical-development plans and brand strategies for assigned TAs. Ensures team contributes as relevant members to the PDT and/or ADT sub-teams (V&I, Value Evidence, Clinical, Commercial, Publications, and Label teams).
• Integrates end-to-end knowledge gaps across countries and regions to better inform the GMSA portion of our Global V&I plans, enabling the countries and regions to successfully implement their country or regional priorities.
• Applies expertise in country’s medical systems and clinical practice standards to guide Global Directors Medical Affairs (GDMAs) and/or Regional Directors Medical Affairs (RDMAs) and partners with Regional Strategy Leads (RSLs) to anticipate challenges, identify solutions, and implement actions that support adoption of new innovations. Monitors external clinical trends and scientific developments through systematic insight collection from group input meetings (GIMs), congresses, and other platforms to maintain up-to-date knowledge of emerging science, medicines, and vaccines.
• Demonstrates business acumen by guiding the team to ask insightful, elevated questions and challenge the status quo. Leverages assessments to integrate actionable medical insights from various countries and regions, informing both current and future needs of the global strategy, ultimately ensuring insights are implemented into actions and goals.
• Leads the team in engagement with international scientific leaders and other key stakeholders (therapeutic guideline committees, payers, public groups, government officials, medical societies) about our company’s emerging science.
• E…